Early Treatment for Myelodysplastic Syndrome: Many Patients Are Missing Out

Video

Many patients with myelodysplastic syndrome are not receiving early treatment.

About two-thirds of patients with myelodysplastic syndrome (MDS) are not being given early treatment, according to Christopher Cogle, M.D., a professor of Medicine at the University of Florida Health.

Cogle was involved with a study that examined which patients were more likely to be treated with Vidaza (azacitidine), Dacogen (decitabine) or Revlimid (lenalidomide). While he initially thought that age and frailness would be the factors that were associated with not being treated, he actually found that it was patients with higher-risk disease, private insurance and genetic testing who were more likely to be prescribed one of the three agents.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Related Content
Image of "FDA Approval: What You Need to Know."

FDA-Approved Rytelo a ‘Game Changer’ for Some Patients with MDS

Alex Biese
June 17th 2024
Article

Approximately half of the patients with MDS who responded to treatment Rytelo went a year without needing a blood transfusion, one expert explained.

Read More

Sharing Breast Cancer Experiences is the ‘Most Special Thing’

Sharing Breast Cancer Experiences is the ‘Most Special Thing’

Ashley Chan
June 12th 2024
Article

Having social media platforms to share breast cancer experiences changes the narrative for others who may empathize, a survivor and advocate said.

Read More

Image of FDA approved.

FDA Approves Rytelo for Some With Low- to Intermediate-1-risk MDS

Alex Biese
June 7th 2024
Article

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Read More

Image of red blood cells moving in a stream.

Reblozyl Continues to Improve MDS Transfusion Independence

Brielle Benyon
June 3rd 2024
Article

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

Read More

Image of a person pouring pills into their hands.

Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS

Ashley Chan
June 3rd 2024
Article

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

Read More

cartoon image of blogger and MDS survivor, Jane Biehl

Cancer Remission Is Wonderful But Scary

Jane Biehl Ph.D.
May 27th 2024
Article

I’ve experienced mixed emotions during my periods of remission for my myelodysplastic syndrome.

Read More